601607 Shanghai Pharmaceuticals Holding
- 19.00
- -0.32-1.66%
Shanghai Pharmaceuticals Holding News
Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Business And Shares Still Trailing The Market
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Shanghai Pharmaceuticals Secures Approval for Production of Pain, Inflammation Capsule
CICC: The pharmaceutical sector has entered a value investment range, focusing on the domestic innovative drug industry chain and going overseas.
China International Capital Corporation released a research report stating that after three years of systematic adjustment, the pharmaceutical sector has entered the range of value investment.
Guotou Securities: The market share of listed pharmacies continues to increase, and the growth potential is expected to lead the industry.
In the context of a slowdown in the industry's growth rate, listed pharmacies are expected to achieve growth rates higher than the industry by virtue of their continuous rapid expansion of stores.
sh pharma (601607.SH): Approval granted for the production of Selamectin capsules.
Sh Pharma (601607.SH) announced on August 6th that its controlled subsidiary, Changzhou Pharmaceutical Factory Co., Ltd. (referred to as 'Changzhou Pharmaceutical Factory') received the Drug Registration Certificate (Certificate No. 2024S01765) issued by the State Drug Administration for Celecoxib capsules (referred to as 'the pharmaceutical'), which has been approved for production. Celecoxib capsules are COX-2-specific inhibitors that inhibit the production of prostaglandins by inhibiting cyclooxygenase-2 (COX-2) and are also the world's first selective non-steroidal anti-inflammatory analgesic drug (NSAIDs).
Shanghai Pharmaceuticals Unit's Methylcobalamin Tablets Passes Drug Regulator's Evaluation
Sh Pharma (601607.SH): The consistency evaluation of Mecobalamin tablets for generic drugs has been approved.
Sh Pharma (601607.SH) announced that its holding subsidiary, Shanghai Xinya Pharmaceutical Co., Ltd. in Minhang, has recently...
China International Capital Corporation: Peptide production ushers in the opportunities of the times with the rapid expansion of GLP-1.
In terms of the global pattern, Swiss companies are leading in peptide production, while China is the main supplier of GLP-1 active pharmaceutical ingredients.
Shanghai supports the use of AI technology in drug research and development, and continues to increase its support for the development of innovative drugs.
On July 30, the Shanghai Municipal People's Government Office issued several opinions on supporting the innovative development of the entire biomedical industry chain.
Shanghai Pharmaceuticals Gets Nod to Register Schizophrenia Drug
Hong Kong stock concept tracking | Diabetes prevention and control action plan released, significant progress has been made in the innovative drug research and development of these enterprises (with concept stocks).
According to Frost & Sullivan data, the scale of China's diabetes medication market is expected to reach 167.5 billion yuan by 2030.
Sh Pharma (02607.HK): Hydrochloride Lurasidone tablets approved for production.
Recently, the salted rulaxine tablets of Changzhou Pharmaceutical Factory Co., Ltd. (hereinafter referred to as "Changzhou Pharmaceutical Factory") received the "Drug Registration Certificate" (certificate number: 2024S01697) issued by the National Medical Products Administration (hereinafter referred to as the "National Medical Administration"). The drug has been approved for production.
Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration
Sh Pharma (601607.SH): Approval for production of Apalutamide Ethanolamine Tablets
On July 23, Gelonghui reported that Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Changzhou Pharmaceutical Factory Co., Ltd. ("Changzhou Pharmaceutical Factory"), received the Drug Registration Certificate (Certificate No.: 2024S01665) approved for production by the National Medical Products Administration for the drug, Epacadostat Ethylamide Tablets. The drug is used to treat chronic immune thrombocytopenia (ITP) in adults and children over six years old who have had a poor response to glucocorticoids, immunoglobulins, and other treatments, increasing platelet counts and reducing or preventing symptoms.
Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Citigroup: Maintains a "buy" rating for Sh Pharma with a lowered target price of HKD 16.2.
According to a research report released by Citigroup, the earnings per share forecast for Shanghai Pharma in the next two years has been reduced by 13.4% and 13.2% respectively to reflect the slowdown in industry growth in the second quarter of this year. The target price has been lowered from HKD 17.5 to HKD 16.2, while the "buy" rating is maintained. The report states that the management of Shanghai Pharma mentioned in a recent conference call that the company will continue to face pressure in its manufacturing business in the second quarter due to the price reduction of polymyxin B. As for the distribution business, the company's second-quarter performance remained above the industry average, benefiting from the strong growth momentum of innovative drugs, medical equipment and medical beauty sectors.
Citigroup: Maintains 'buy' rating for Sh Pharma (02607), target price lowered to HKD 16.2.
Citigroup has lowered its earnings per share forecasts for sh pharma (02607) by 13.4% and 13.2% for the next two years.
Shanghai Pharmaceuticals Holding Co., Ltd Declares $0.2233 Dividend
Shanghai Pharmaceuticals Unit's Anesthesia Passes Regulatory Evaluation
Analysis
Price Target
No Data
